Correlation Between Leap Therapeutics and Checkpoint Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Leap Therapeutics and Checkpoint Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Leap Therapeutics and Checkpoint Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Leap Therapeutics and Checkpoint Therapeutics, you can compare the effects of market volatilities on Leap Therapeutics and Checkpoint Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Leap Therapeutics with a short position of Checkpoint Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Leap Therapeutics and Checkpoint Therapeutics.

Diversification Opportunities for Leap Therapeutics and Checkpoint Therapeutics

-0.05
  Correlation Coefficient

Good diversification

The 3 months correlation between Leap and Checkpoint is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Leap Therapeutics and Checkpoint Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Checkpoint Therapeutics and Leap Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Leap Therapeutics are associated (or correlated) with Checkpoint Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Checkpoint Therapeutics has no effect on the direction of Leap Therapeutics i.e., Leap Therapeutics and Checkpoint Therapeutics go up and down completely randomly.

Pair Corralation between Leap Therapeutics and Checkpoint Therapeutics

Given the investment horizon of 90 days Leap Therapeutics is expected to under-perform the Checkpoint Therapeutics. In addition to that, Leap Therapeutics is 1.2 times more volatile than Checkpoint Therapeutics. It trades about -0.24 of its total potential returns per unit of risk. Checkpoint Therapeutics is currently generating about 0.07 per unit of volatility. If you would invest  335.00  in Checkpoint Therapeutics on December 29, 2024 and sell it today you would earn a total of  69.00  from holding Checkpoint Therapeutics or generate 20.6% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Leap Therapeutics  vs.  Checkpoint Therapeutics

 Performance 
       Timeline  
Leap Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Leap Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Checkpoint Therapeutics 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Leap Therapeutics and Checkpoint Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Leap Therapeutics and Checkpoint Therapeutics

The main advantage of trading using opposite Leap Therapeutics and Checkpoint Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Leap Therapeutics position performs unexpectedly, Checkpoint Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Checkpoint Therapeutics will offset losses from the drop in Checkpoint Therapeutics' long position.
The idea behind Leap Therapeutics and Checkpoint Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data